Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18893410 | 0.86 | GAA (0.44) | GAALMNAMAPTALDH1A1TDP1 | |
| SCHEMBL2823284 | 0.85 | GAA (0.47) | GAALMNAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31757677 | 0.81 | ALDH1A1 (0.42) | GAAMAPTALDH1A1RAB9A | |
| SCHEMBL22874663 | 0.80 | LTA4H (0.44) | ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL3372005 | 0.79 | ALDH1A1 (0.57) | GAAMAPTALDH1A1TDP1L3MBTL1 | |
| SCHEMBL20512947 | 0.79 | GAA (0.54) | GAALMNAMAPTALDH1A1TDP1 | |
| SCHEMBL27645827 | 0.79 | MEN1 (0.43) | GAAMAPTALDH1A1TDP1L3MBTL1 | |
| SCHEMBL3117689 | 0.79 | RAB9A (0.45) | GAAMAPTALDH1A1TDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL14999773 | 0.78 | GAA (0.53) | GAALMNAMAPTALDH1A1TDP1 | |
| SCHEMBL19072872 | 0.78 | ALDH1A1 (0.40) | GAALMNAMAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3381915-B1 | LACTAM COMPOUND DERIVATIVE AND APPLICATION THEREOF | NHWA PHARMA CORP (CN) | 2023-01-18 | — | — | EP | disclosed |
| EP-3483149-B1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | YUHAN CORP (KR) | 2021-01-13 | — | — | EP | disclosed |
| US-10689331-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-10383859-B2 | Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same | YUHAN CORPORATION (KR) | 2019-08-20 | — | — | US | disclosed |
| US-20190142809-A1 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | YUHAN CORPORATION (KR) | 2019-05-16 | — | — | US | disclosed |
| EP-3483149-A1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Yuhan Corporation (KR) | 2019-05-15 | — | — | EP | disclosed |
| US-20190002402-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180327397-A1 | LACTAM COMPOUND DERIVATIVE AND APPLICATION THEREOF | NHWA PHARMA. CORPORATION (CN) | 2018-11-15 | — | — | US | disclosed |
| EP-3381915-A1 | LACTAM COMPOUND DERIVATIVE AND APPLICATION THEREOF | NHWA Pharma Corporation (CN) | 2018-10-03 | — | — | EP | disclosed |
| US-7928135-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1651229-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | Chiron Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| US-7034033-B2 | Substituted quinazolinone compounds | CHIRON CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060030573-A1 | Substituted quinazolinone compounds | BOYCE RUSTUM S | 2006-02-09 | — | — | US | disclosed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | disclosed |
| EP-1551834-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | CHIRON CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005051391-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | disclosed |
| WO-2004112793-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040019049-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2003099818-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | CHIRON CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059662-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | GAA 2324/4885LMNA 3489/4885MAPT 4380/4885 |
| US-20190142809-A1 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | ILK, SBDS, BDKRB1 | GAA 4292/4885LMNA 619/4885MAPT 2062/4885 |
| US-10383859-B2 | Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same | ILK, SBDS, BDKRB1 | GAA 4292/4885LMNA 619/4885MAPT 2062/4885 |
| US-20040019049-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | GAA 2595/4885LMNA 3598/4885MAPT 4456/4885 |
| US-20060030573-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | GAA 2628/4885LMNA 3612/4885MAPT 4503/4885 |
| US-20180327397-A1 | LACTAM COMPOUND DERIVATIVE AND APPLICATION THEREOF | BACE1, QPCT, PSENEN | GAA 1134/4885LMNA 3577/4885MAPT 1508/4885 |
| US-20190002402-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | GAA 337/4885LMNA 4498/4885MAPT 1988/4885 |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | MC4R, MC2R, MC3R | GAA 1194/4885LMNA 3436/4885MAPT 4307/4885 |
| US-10689331-B2 | IDO inhibitors | IDO1, IDO2, INMT | GAA 337/4885LMNA 4498/4885MAPT 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.